Clinical Trial: Chikungunya Virus Vaccine Trial in Healthy Adults

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

Brief Summary:

Background:

- Chikungunya virus (CHIKV) is transmitted by mosquitoes. It can cause fever, headache, muscle pain, fatigue, and joint pain. The disease usually does not cause death. But the joint pain, which may be directly related to the infecting virus, may be severe and last for several months. CHIKV outbreaks are most common in Africa, India, and Asia. A new experimental vaccine for CHIKV has been developed, and researchers are testing it in healthy adults. Participants cannot develop CHIKV from this vaccine.

Objectives:

- To test the safety and effectiveness of a Chikungunya virus vaccine.

Eligibility:

- Healthy individuals between 18 and 50 years of age.

Design:

  • This study, including vaccine doses and followup tests, will last about 44 weeks. Participants will have three vaccination visits, six followup clinic visits, and three telephone contacts during this study. Vaccination visits will take about 4 hours. Most other clinic visits will usually take 2 hours. The telephone contacts will take about 15 minutes.
  • Participants will be screened with a physical exam and medical history. Blood samples will also be collected.
  • Participants will be assigned to one of three dose groups. Information about doses will be provided before the start of the vaccinations.
  • Vaccine injections will be given at the start of the study, at 4 weeks, and at 20 weeks. Participants will be asked to keep an eye on the injection site for 7 days and to notify researchers

    Detailed Summary:

    This is a Phase I, open-label, dose-escalation study to examine the safety, tolerability, and immune response to a Virus-Like Particle (VLP) Chikungunya Virus (CHIKV) vaccine in healthy adults ages 18 to 50 years old. The plan is for 25 subjects to receive 3 intramuscular vaccine injections at weeks 0, 4, and 20. The three groups will be enrolled sequentially starting with the lowest dose of 10 micrograms per injection in Group 1.

    The hypothesis is that the vaccine is safe and induces immune responses to CHIKV. The primary objective is to evaluate the safety and tolerability of the investigational vaccine, VRC-CHKVLP059-00-VP, at three dosages, 10 micrograms (mcg), 20 mcg, and 40 mcg, in healthy adults. The secondary objective is to evaluate the antibody response against CHIKV VLPs four weeks after the third vaccine injection. The exploratory objectives relate to antigen-specific humoral and cellular immune responses throughout the study.


    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

    Current Primary Outcome:

    • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of First Vaccination [ Time Frame: 7 days after the first vaccination ]
      Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after first vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.
    • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Second Vaccination [ Time Frame: 7 days after the second vaccination ]
      Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after second vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number reporting one or more local symptom at any severity.
    • Number of Subjects Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Third Vaccination [ Time Frame: 7 days after the third vaccination ]
      Subjects record the occurrence of solicited symptoms on a Memory Aid for 7 days after third vaccination and review the Memory Aid with clinic staff at follow a up visit. Subjects are counted once for each symptom if they indicated experiencing the symptom at any severity during the reporting period. The number reported for all local symptoms is the number report

      Original Primary Outcome: The primary objective of the study is the safety and tolerability of the VRC-CHKVLP059-00-VP vaccine at the three dosage levels when administered intramuscularly.

      Current Secondary Outcome:

      • Chikungunya Antigen-specific ELISA Geometric Mean Titer (GMT) [ Time Frame: 24 weeks after the first vaccination ]
        ELISA titer (strain 37997) For ELISA, week 0 values were used to background correct titres for subsequent weeks.
      • Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) [ Time Frame: Pre-vaccination (Week 0) ]
        Neutralisation IC50 titre (strain OPY1)
      • Chikungunya Antigen-specific Neutralizing Antibody Geometric Mean Titer (GMT) [ Time Frame: 24 weeks after the first vaccination ]
        Neutralisation IC50 titre (strain OPY1)


      Original Secondary Outcome: The secondary objective of the study is to evaluate the antibody response to the vaccine four weeks after the last vaccination.

      Information By: National Institutes of Health Clinical Center (CC)

      Dates:
      Date Received: December 7, 2011
      Date Started: December 2011
      Date Completion:
      Last Updated: June 9, 2016
      Last Verified: March 2016